Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance

The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02502344

Acronym

MIIIROPOAGT

Enrollment

Registered

2015-07-20

Start date

2015-08-31

Completion date

Unknown

Last updated

2016-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance

Keywords

insulin resistance, abnormal glucose tolerance, DM prevention

Brief summary

This research would take medical interventions in subjects of insulin resistance without abnormal glucose tolerance, to see if there were different prevalence of abnormal glucose tolerance in different groups.

Detailed description

The situation of type 2 DM prevention in China is serious. The commonly accepted natural course of type 2 DM is as follows: obesity, insulin resistance(hyperinsulemia), abnormal glucose tolerance, DM and complications of DM; correspondently, the function status of pancreas islet β cells are: normal, compensatory, decompensatory, impaired and failure. Post researches have proved that using medical interventions after the period of insulin resistance when the function status of β cells were compensatory, the course could not be reversed. There were few clinical researches about effects of medical interventions in the period of insulin resistance . This research would take medical interventions in subjects of insulin resistance without abnormal glucose tolerance, to see if there were different prevalence of abnormal glucose tolerance in different groups.

Interventions

BEHAVIORALhealthy lifestyle

food control and intensive exercise to lose weight

DRUGMetformin

use metformin to reduce insulin resistance

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* BMI \> 28kg/m2 * diagnosis of insulin resistance

Exclusion criteria

* abnormal glucose tolerance * function impairment of heart, liver or kidney

Design outcomes

Primary

Measure	Time frame	Description
prevalence of abnormal glucose intolerance	two years after the subject joins the research	OGTT test will be took in these subjects to find out if their glucose tolerance was abnormal

Countries

China

Contacts

Primary ContactZi Q Zeng, Doctor

zzq@btch.edu.cn0086-010-56118899

Backup ContactJian Z Xiao, Doctor

xiaojzh858@sina.com0086-010-56118899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026